IMGN Stock - ImmunoGen Inc.

IMGN Stock Chart

IMGN Profile

ImmunoGen, Inc., a prominent player in the biotechnology sector, specializes in the development of innovative antibody-drug conjugate (ADC) therapies designed to combat cancer. The company's pipeline features several promising product candidates, including mirvetuximab soravtansine targeting folate-receptor alpha (FRa), currently in Phase III clinical trials for platinum-resistant ovarian cancer. Additionally, Pivekimab sunirine, an ADC directed against CD123, is undergoing Phase II clinical trials for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.

In its commitment to advancing cancer treatment, ImmunoGen, Inc. also pursues preclinical programs such as IMGC936, a collaborative effort with MacroGenics, Inc., and IMGN151, an anti-FRa product candidate. The company collaborates with leading pharmaceutical entities including Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., and others, underscoring its strategic approach to innovation through partnerships.

Headquartered in Waltham, Massachusetts, ImmunoGen, Inc. was founded in 1980 and has since established itself as a pivotal player in the biopharmaceutical landscape. Its collaborations extend its research capabilities and bolster its portfolio, aiming to address unmet medical needs in oncology through cutting-edge ADC technologies. With a focus on scientific rigor and therapeutic innovation, ImmunoGen remains dedicated to transforming cancer care and improving patient outcomes globally.

The company's strategic location in the biotech hub of Massachusetts, coupled with its extensive network of collaborations, positions it at the forefront of ADC research and development. ImmunoGen continues to leverage its expertise and partnerships to pioneer novel therapies, striving to redefine standards in cancer treatment and contribute significantly to the advancement of oncology research.

IMGN Revenue Chart

IMGN Earnings

Analyst Ratings